You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: December 22, 2024

Claims for Patent: 6,166,197


✉ Email this page to a colleague

« Back to Dashboard


Summary for Patent: 6,166,197
Title: Oligomeric compounds having pyrimidine nucleotide (S) with 2'and 5 substitutions
Abstract:Oligonucleotide analogs are disclosed having pyrimidine monomeric sub-units therein that are modified at the 2' and 5 positions. Monomeric sub-units having these modifications may be further modified at the 2 position.
Inventor(s): Cook; Phillip Dan (San Marcos, CA), Sanghvi; Yogesh S. (San Marcos, CA), Sprankle; Kelly G. (Vista, CA), Ross; Bruce S. (Carlsbad, CA), Griffey; Rich H. (Vista, CA)
Assignee: ISIS Pharmaceuticals, Inc. (Carlsbad, CA)
Application Number:08/398,901
Patent Claims: 1. An oligomeric compound comprising at least one monomeric sub-unit of structure I: ##STR4## wherein: X is amino;

R is methyl;

L is oxygen;

Z is --O--CH.sub.3 ; and

one of Q.sub.1 and Q.sub.2 is attached via a phosphorothioate linking moiety to a nucleotide, oligonucleotide, nucleoside, or oligonucleoside and the other of said Q.sub.1 and Q.sub.2, is a hydroxyl, a protected hydroxyl, an activated solid support, a nucleotide, an oligonucleotide, a nucleoside, an oligonucleoside, an oligo-nucleotide/nucleoside, an activated phosphate, a phosphate, an activated phosphite, or a phosphite;

provided that said linking moiety is not a sulfamate group.

2. An oligomeric compound comprising at least one monomeric sub-unit of structure I: ##STR5## wherein: X is amino;

R is methyl;

L is oxygen;

Z is O--R.sub.1 X.sub.1, where R.sub.1 is C.sub.1 -C.sub.6 alkyl, and X.sub.1 is H; and

one of Q.sub.1 and Q.sub.2 is attached via a phosphorothioate linking moiety to a nucleotide, oligonucleotide, nucleoside, or oligonucleoside and the other of said Q.sub.1 and Q.sub.2, is a hydroxyl, a protected hydroxyl, an activated solid support, a nucleotide, an oligonucleotide, a nucleoside, an oligonucleoside, an oligo-nucleotide/nucleoside, an activated phosphate, a phosphate, an activated phosphite, or a phosphite;

provided that said linking moiety is not a sulfamate group.

3. An oligomeric compound comprising at least one monomeric sub-unit of structure I: ##STR6## wherein: X is amino;

R is methyl;

L is oxygen;

Z is O--R.sub.1 X.sub.1, where R.sub.1 is substituted C.sub.1 -C.sub.6 alkyl, and X.sub.1 is H; and

one of Q.sub.1 and Q.sub.2 is attached via a phosphorothioate linking moiety to a nucleotide, oligonucleotide, nucleoside, or oligonucleoside and the other of said Q.sub.1 and Q.sub.2, is a hydroxyl, a protected hydroxyl, an activated solid support, a nucleotide, an oligonucleotide, a nucleoside, an oligonucleoside, an oligonucleotide/nucleoside, an activated phosphate, a phosphate, an activated phosphite, or a phosphite;

provided that said linking moiety is not a sulfamate group.

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.